4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have received an average rating of "Moderate Buy" from the eight ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $26.71.

Several research firms have recently weighed in on FDMT. Bank of America reduced their price objective on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, March 10th. BMO Capital Markets cut shares of 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. Chardan Capital cut their price objective on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research report on Thursday, April 24th. Finally, HC Wainwright reissued a "buy" rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS acquired a new stake in 4D Molecular Therapeutics during the fourth quarter worth approximately $48,000. Point72 Asia Singapore Pte. Ltd. bought a new position in 4D Molecular Therapeutics during the 4th quarter worth $50,000. PNC Financial Services Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 66.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock worth $51,000 after buying an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in shares of 4D Molecular Therapeutics by 5,291.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock valued at $55,000 after acquiring an additional 9,737 shares during the period. Finally, Velan Capital Investment Management LP acquired a new position in shares of 4D Molecular Therapeutics in the fourth quarter valued at about $56,000. Institutional investors and hedge funds own 99.27% of the company's stock.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ FDMT opened at $3.57 on Tuesday. 4D Molecular Therapeutics has a 52-week low of $2.24 and a 52-week high of $28.93. The stock has a market cap of $165.38 million, a P/E ratio of -1.25 and a beta of 2.87. The firm has a 50 day moving average price of $3.47 and a 200 day moving average price of $5.40.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10). Analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.